NovaBay Pharmaceuticals, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Kazley
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2000 Powell Street EmeryVille CA United States of America 94608
- IPO Date
- Oct 26, 2007
- CIK
- 0001389545
- Website
- novabay.com
- Similar Companies
- Business
- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) develops and commercializes anti-infective products based on proprietary hypochlorous acid (HOCl) technology for eye care, wound care, and skin care applications; its core offerings include Avenova Antimicrobial Lid and Lash Solution for blepharitis and dry eye management, NeutroPhase and PhaseOne branded wound cleansers for debridement and infection control in acute and chronic wounds, and DERMAdoctor skincare products targeting antimicrobial needs. Founded in 2000 and headquartered in Emeryville, California, the company operates primarily in the United States through prescription and over-the-counter channels, serving ophthalmologists, optometrists, dermatologists, hospitals, long-term care facilities, and consumers via online and professional distribution. In August 2025, NovaBay entered a $6 million securities purchase agreement with investor David E. Lazar, who provided an initial $3.85 million for Series A preferred stock, assumed the roles of CEO and board director, and committed funds to maintain the NYSE American listing, pursue strategic transactions such as acquisitions, and enable a special cash dividend in Q3 2025 pending shareholder approval; this followed shareholder authorization for potential dissolution and marked a leadership transition from prior CEO Justin Hall to Vice President of Business Development, alongside a recent S-3/A shelf registration for up to $200 million in securities as the company shifts away from core eyecare and wound care segments.
NovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19%
NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update
Why Did KALA BIO Shares Jump Over 22% After Hours?
What Sparked KALA BIO's Nearly 38% Surge Overnight?
NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting
NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand
NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.'s Avenova Brand and Business Is Fair to Shareholders
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results
NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million